Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 233Neoplasms 163Prostatic Neoplasms 143Colorectal Neoplasms 105Lung Neoplasms 97Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 72Carcinoma, Non-Small-Cell Lung 71Multiple Myeloma 61Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Melanoma 51Glioblastoma 48Carcinoma, Hepatocellular 45Ovarian Neoplasms 44Head and Neck Neoplasms 43Uterine Cervical Neoplasms 41Neoplasm Metastasis 41Sarcoma 40Glioma 39Stomach Neoplasms 37Hematologic Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Recurrence 35Lymphoma, Non-Hodgkin 34Carcinoma, Renal Cell 34Esophageal Neoplasms 33Lymphoma 32Leukemia 32Rectal Neoplasms 31

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Autistic Disorder × 30 days × Clear all
NCT07218575 2026-06-04

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Boston Children's Hospital

Phase 2/3 Not yet recruiting
60 enrolled

Autistic Disorder, Hamartoma Syndrome, Multiple

Data powered by HemOnc (CC BY 4.0) Colophon âš¡